首页> 外国专利> A method for producing in the interior a in oil emulsified hydrophilic flue signal containing a function of the very small particles by simple coacervation

A method for producing in the interior a in oil emulsified hydrophilic flue signal containing a function of the very small particles by simple coacervation

机译:一种通过简单凝聚在内部产生包含极小颗粒功能的油中乳化亲水烟道信号的方法

摘要

Microcapsules composed of a gellable hydrophilic colloid enclosing a water-in-oil emulsion containing an "anti-inversion agent" in the oil phase and prepared by a coacervation process (see Group VI) comprise the dye D and C Green No. 5 dissolved in the aqueous phase of the emulsion. Suitable colloids are gelatin, agar, casein, albumin, pectins, starch and fibrinogen and the anti-inversion agent may be non-ionic surfactant, hydrogenated castor oil, a solid fat, a sterol or a natural or synthetic wax. Specification 751,600 is referred to.ALSO:Microcapsules for use in fertilizers as a source of nitrogen consist of an aqueous urea-in-oil emulsion contained within a mantle of a gellable hydrophilic colloid, e.g. gelatin, agar, albumen, casein, pectins, starch or fibrinogen, the oil phase of the emulsion (e.g. corn oil) containing an "anti-inversion agent", e.g. hydrogenated castor oil or a solid fat, sterol or natural or synthetic wax or a non-ionic surfactant. They are produced by a concervation process whereby the colloid is caused to deposit from an aqueous roll thereof on to emulsion particles suspended therein the capsule walls subsequently being gelled and hardened (see Group VI). Specification 751,600 is referred to.ALSO:Particles of a hydrophilic liquid-in-oil emulsion are encapsulated by a process wherein the said emulsion containing an anti-inversion agent in the oil phase is dispersed in a coacervating solution comprising a coacervating agent and an aqueous sol of a coacervating colloid at a temperature above the gel point of the said colloid to form a secondary emulsion upon which the coacervate is deposited and which may subsequently be gelled and hardened by cooling and treatment with a hardener or plasticizer e.g. aqueous formaldehyde. A conventional thickening agent e.g. acacia, tragacanth, methyl- or carboxymethyl-cellulose, magnesium aluminium silicate, polyglycols, glycerin or syrups may be added to both the internal hydrophilic liquid phase and to the coacervating solution, and conventional emulsifying agents may be used in the preparation of the primary emulsion. The anti-inversion agent may be any which is capable of preventing the inversion of the primary emulsion on its dispersion in the coacervating solution e.g. surface active agents (preferably non-ionic) e.g. sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters and oil thickening agents e.g. natural and synthetic waxes, solid fats, sterols and ethyl cellulose. Suitable coacervating colloids are gelable hydrophilic colloids e.g. gelatin (preferred), agar-agar, alginates, casein, pectins, starch and fibrinogen. The coacervating agent may be an electrolyte e.g. a salt having an alkali or alkali metal cation and an organic or inorganic anion or a water soluble solvent in which the coacervating colloid is less soluble than it is in water. The primary emulsion particles may contain additional materials dissolved or suspended in either or both phases, e.g. pharmaceuticals, vitamins, cosmetic ingredients, fertilizers, plant growth hormones, fungicides, bactericides, viricides and pesticides. Specific examples relate inter alia to encapsulated emulsions comprising: (a) urea in an internal aqueous phase (fertilizer preparation); (b) cod liver oil (oil phase) and ascorbic acid (aqueous phase) for incorporation into dry cereals; (c) neomycin (aqueous phase) for incorporation into ointments; (d) an ethanolic solution of ethylene dibromide in peanut oil (nematocidal preparation). Reference is also made to orally and parenterally administrable pharmaceutical forms which may have sustained release characteristics. Detailed examples of the preparation of the capsules are given. Specification 751,600 is referred to.
机译:微胶囊由可凝胶化的亲水性胶体组成,该胶体在油相中包含油包水乳液,该乳液中含有“抗转化剂”,并且通过凝聚法制备(参见第VI组),该微胶囊包含溶解在其中的染料D和C绿色5号。乳液的水相。合适的胶体是明胶,琼脂,酪蛋白,白蛋白,果胶,淀粉和纤维蛋白原,并且抗转化剂可以是非离子表面活性剂,氢化蓖麻油,固体脂肪,固醇或天然或合成蜡。参见规格751,600。ALSO:用于肥料中作为氮源的微胶囊由包含在可胶凝的亲水性胶体(例如聚乙烯醇)的套中的油包水型尿素包水乳液组成。明胶,琼脂,白蛋白,酪蛋白,果胶,淀粉或纤维蛋白原,乳剂的油相(例如玉米油)中含有“抗转化剂”,例如氢化蓖麻油或固体脂肪,固醇或天然或合成蜡或非离子表面活性剂。它们通过浓缩方法生产,由此使胶体从其水性辊上沉积到悬浮在胶囊壁中的乳液颗粒上,随后将其胶凝和硬化(参见第VI组)。参见规格751,600。ALSO:通过以下方法将亲水性油包液乳液的颗粒包封,其中将所述在油相中包含抗转化剂的乳液分散在包含凝聚剂和水的凝聚溶液中。凝聚胶体的溶胶在高于所述胶体的凝胶点的温度下形成第二乳液,凝聚剂沉积在其上,随后可通过冷却和用硬化剂或增塑剂处理而凝胶化和硬化。甲醛水溶液。常规的增稠剂例如可以将阿拉伯胶,黄,胶,甲基或羧甲基纤维素,硅酸铝镁,聚乙二醇,甘油或糖浆添加到内部亲水液相和凝聚溶液中,并且常规乳化剂可以用于制备初级乳液。所述抗转化剂可以是任何能够防止所述初级乳液在其分散于凝聚溶液中时转化的乳液,例如所述乳液。表面活性剂(优选非离子的)例如失水山梨糖醇脂肪酸酯,聚氧乙烯失水山梨糖醇脂肪酸酯和油增稠剂例如天然和合成蜡,固体脂肪,固醇和乙基纤维素。合适的凝聚胶体是可胶凝的亲水胶体,例如胶体。明胶(首选),琼脂,藻酸盐,酪蛋白,果胶,淀粉和纤维蛋白原。凝聚剂可以是电解质,例如电解质。具有碱或碱金属阳离子和有机或无机阴离子的盐或水溶性溶剂,其中凝聚胶体的溶解性低于其在水中的溶解性。初级乳液颗粒可以包含溶解或悬浮在任一相或两相中的另外的材料,例如碳酸氢钠。药品,维生素,化妆品成分,肥料,植物生长激素,杀真菌剂,杀菌剂,杀病毒剂和农药。具体的例子尤其涉及包囊的乳液,其包含:(a)在内部水相中的尿素(肥料制剂); (b)将鳕鱼肝油(油相)和抗坏血酸(水相)掺入干谷物中; (c)新霉素(水相),可掺入药膏中; (d)花生油中的二溴乙烷的乙醇溶液(杀线虫剂)。还提到了可以具有持续释放特性的口服和肠胃外给药的药物形式。给出了胶囊制备的详细实例。参考规格751,600。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号